Infectious DiseasePoster 31Intraoral Manifestations in a Patient with Trigeminal Trophic Syndrome: A Case Study Authors: Andres Davila, DMD; Roopali Mahajan, BDS,...
Infectious DiseasePoster 32Predictors of COVID-19 Disease Severity Augment the Braden Scale in the Prediction of Pressure Ulcer Development among COVID-19-Positive...
Infectious DiseasePoster 33Efficacy of Omadacycline in the Treatment of Acute bacterial Skin and Skin Structure Infections in Patients with Cellulitis or Abscesses
Infectious DiseasePoster 34Pooled Results of VP-102 Safety and Efficacy in Phase 3 Trials for Molluscum Contagiosum by Fitzpatrick Skin Type (FST)
PsoriasisPoster 35Long-term safety and efficacy of roflumilast cream 0.3% in adult patients with chronic plaque psoriasis: results from a 52-week...
PsoriasisPoster 36Roflumilast cream, a once-daily, potent phosphodiesterase-4 inhibitor, in chronic plaque psoriasis patients: Efficacy and safety...
PsoriasisPoster 37Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients With Moderate to Severe Plaque Psoriasis Who Had Inadequate...
PsoriasisPoster 38Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, Versus Placebo in Scalp, Nail, and Palmoplantar Psoriasis...
PsoriasisPoster 39Deucravacitinib Long-term Efficacy and Safety in Plaque Psoriasis: 2-Year Results From the Phase 3 POETYK PSO Program
PsoriasisPoster 40Tapinarof Cream 1% Once Daily for Plaque Psoriasis: Efficacy by Baseline Disease Characteristics and Demographics in Two Pivotal Phase 3...
PsoriasisPoster 41Efficacy and Safety of Calcipotriene Topical Foam 0.005% in Maintenance Treatment of Moderate Plaque-Type Psoriasis After Combination...
PsoriasisPoster 42Patient Preference for Calcipotriene/Betamethasone Fixed Combination Cream vs Foam: A Pilot Study
PsoriasisPoster 43Effectiveness, safety, and quality of life from a Phase 4 real-world study of tildrakizumab in patients with moderate-to-severe psoriasis
PsoriasisPoster 44Maintenance of bimekizumab efficacy through 2 years in patients with moderate to severe plaque psoriasis: Pooled results from five...
PsoriasisPoster 45Bimekizumab infection rates in patients with moderate to severe plaque psoriasis: Analysis of pooled data from 2 years of treatment...